Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07148180 · ClinicalTrials.gov registry record · Phase 1

A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax

A Phase 1 study of Leukemia and Blood Cancer, sponsored by Jacqueline Garcia, MD.

Recruiting
Registry status
Phase 1
Development phase
31
Enrollment target
2
Study locations

NCT07148180 is a Phase 1 study of Leukemia and Blood Cancer that is actively recruiting participants, run by Jacqueline Garcia, MD. The registered enrollment target is 31 participants, below the 487-participant average among 233 other Leukemia trials with a reported enrollment target (94% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07148180, a Phase 1 study of Leukemia and Blood Cancer, is actively recruiting participants, sponsored by Jacqueline Garcia, MD.

RECRUITING
Registry status
Phase 1
Development phase
31 participants
Enrollment target
2
Study locations

Study Summary

The purpose of this research study is to test the safety and efficacy of a new drug combination with three agents, azacitidine, venetoclax and tagraxofusp. Leftover (residual) leukemia disease that is not visible by eye can be increase the chance of disease recurrence. This research study is to determine if the combination therapy can safely help to control residual Acute Myeloid Leukemia (AML) and to prevent disease recurrence. The names of the study drugs involved in this study are: * Tagraxofusp (a type of CD123-directed cytotoxin) * Azacitidine (a type of standard of care cytidine nucleoside analog) * Venetoclax (a type of standard of care BCL-2 inhibitor)

Conditions Studied

Leukemia Blood Cancer Acute Myeloid Leukaemia (AML) Blood Cancers

Interventions

  • DRUG Venetoclax
  • DRUG Tagraxofusp
  • DRUG Azacitidine (AZA)

Study Locations (2)

Massachusetts

  • Brigham and Women's Hospital - Boston
  • Dana-Farber Cancer Institute - Boston

Trial Details

FieldValue
Enrollment Target 31 participants
Start Date 2026-02-02
Est. Completion 2030-12-31
Phase Phase 1

Sponsor

Jacqueline Garcia, MD

5 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07148180

The ClinicalTrials.gov registry entry for NCT07148180 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 487-participant average among 233 other Leukemia trials with a reported enrollment target (94% lower). The listed sponsor is Jacqueline Garcia, MD, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Leukemia appearing as the primary indexed condition, and to 3 interventions - of which Venetoclax is the first listed.

NCT07148180 reports 2 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT07148180 about?

NCT07148180 is a clinical study titled "A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax". The purpose of this research study is to test the safety and efficacy of a new drug combination with three agents, azacitidine, venetoclax and tagraxofusp. Leftover (residual) leukemia disease that is not visible by eye can be increase the chance of disease recurrence. This research study is to dete...

What is the current status of trial NCT07148180?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2026-02-02. Estimated completion is 2030-12-31.

What conditions does trial NCT07148180 study?

This clinical trial studies the following conditions: Leukemia, Blood Cancer, Acute Myeloid Leukaemia (AML), Blood Cancers.

What interventions are being tested in trial NCT07148180?

The interventions under investigation include: Venetoclax (DRUG), Tagraxofusp (DRUG), Azacitidine (AZA) (DRUG).

Who is sponsoring clinical trial NCT07148180?

This trial is sponsored by Jacqueline Garcia, MD, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07148180 being conducted?

This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Leukemia

All registered trials for this condition

Blood Cancer

All registered trials for this condition

Massachusetts

All trials with a study site in Massachusetts

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.